News stories about Arena Pharmaceuticals (NASDAQ:ARNA) have been trending somewhat positive on Monday, according to Accern. Accern scores the sentiment of news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Arena Pharmaceuticals earned a media sentiment score of 0.08 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 45.960719285404 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
A number of research firms recently weighed in on ARNA. Leerink Swann reiterated a “positive” rating and issued a $56.00 price objective (up from $53.00) on shares of Arena Pharmaceuticals in a research note on Wednesday, January 17th. BidaskClub lowered shares of Arena Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, March 13th. Needham & Company LLC upgraded shares of Arena Pharmaceuticals from a “hold” rating to a “buy” rating and lifted their price objective for the company from $30.89 to $60.00 in a research note on Tuesday, March 20th. JMP Securities lifted their price objective on shares of Arena Pharmaceuticals from $63.00 to $79.00 and gave the company an “outperform” rating in a research note on Tuesday, March 20th. Finally, ValuEngine upgraded shares of Arena Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, March 22nd. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $53.13.
Shares of NASDAQ:ARNA opened at $35.68 on Monday. The company has a quick ratio of 3.89, a current ratio of 3.89 and a debt-to-equity ratio of 0.28. Arena Pharmaceuticals has a one year low of $11.30 and a one year high of $45.85. The firm has a market capitalization of $1,704.81, a price-to-earnings ratio of -13.57 and a beta of 1.48.
WARNING: “Arena Pharmaceuticals (ARNA) Earning Somewhat Positive Media Coverage, Study Shows” was posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://www.chaffeybreeze.com/2018/04/16/arena-pharmaceuticals-arna-earning-somewhat-positive-media-coverage-study-shows.html.
About Arena Pharmaceuticals
Arena Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn’s disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH).
Receive News & Ratings for Arena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.